Assessing the role of Mac-2 binding protein glycosylation isomer in the management of patients with chronic hepatitis B

Figure 1 The distribution of Mac-2 binding protein glycosylated isomer levels in healthy volunteers. M2BPGi: Mac-2 binding protein glycosylated isomer; C.O.I: Cut-off index.

Figure 2 Median of Mac-2 binding protein glycan isomer levels between different fibrosis stages. ^aKruskal-Wallis test, P < 0.05; M2BPGi: Mac-2 binding protein glycosylated isomer; C.O.I: Cut-off Index.

Figure 3 Median of Mac-2 binding protein glycan isomer levels between different fibrosis stages. ^aKruskal-Wallis test, P < 0.05; C.O.I: Cut-off Index.

Figure 4 Area under the receiver operating characteristic curves depicting diagnostic performance of noninvasive marker. A: Area under the receiver operating characteristic curve (AUROC) of significant fibrosis; B: AUROC of advanced fibrosis; C: AUROC of cirrhosis. M2BPGi: Mac-2 binding protein glycosylated isomer; APRI: Aspartate transaminase to platelet ratio index; FIB-4: Fibrosis-4 index; AUC: Area under the curve.

Figure 5 Relative changes of Mac-2 binding protein glycosylated isomer, Fibroscan, and Alanin Aminotransferase over first 6 months of antiviral treatment. M2BPGi: Mac-2 binding protein glycosylation isomer; ALT: Alanine transaminase; C.O.I: Cut-off index; kPa: Kilopascal.